Mandel-Brehm Josh 4
4 · Camp4 Therapeutics Corp · Filed Oct 15, 2024
Insider Transaction Report
Form 4
Mandel-Brehm Josh
DirectorChief Executive Officer
Transactions
- Conversion
Series B Preferred Stock
2024-10-15−6,791→ 0 total→ Common Stock (605 underlying) - Conversion
Common Stock
2024-10-15+605→ 272,357 total
Footnotes (1)
- [F1]On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering.